A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.

Study Identifier
THAI-03-002
CT.gov Identifier
NCT00234988
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Obesity or Weight Loss
    • Study Drug
  • sibutramine hydochloride monohydrate
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subject has nutritional obesity and BMI >30 kg/m
    Exclusion Criteria:
    - Type 1 or type 2 diabetes mellitus - Inadequately controlled hypertension - History of Gilles de la Tourette's Syndrome. - Use of any MAOIs, SSRIs, amino acids, antimigraine drugs, opioids - Hypothyroidism or hyperthyroidism. - History of: - benign prostatic hyperplasia - neurological disorders - psychiatric illness - severe renal or hepatic impairments - narrow-angle glaucoma - History of cardiovascular disease or cerebrovascular disease - Persistent tachycardia at rest - Pulmonary hypertension - Phaeochromocytoma

    Protocol Summary

    The purpose of the study is to determine the safety and weight loss when sibutramine is used

    in overweight and obese subjects.

    Study Locations

    Location
    Status
    Location
    Global Medical Information - Abbott
    North Chicago, Illinois, United States, 60064
    Status
    Not applicable